

<u>Field Name</u>	<u>Field Description</u>
<u>Prior Authorization Group Description</u>	<u>Insulin Pumps</u>
<u>Drugs</u>	<p><u>Omnipod Dash, insulin delivery pods only</u> <u>(Notes: The Omnipod Dash PDM (Personal Diabetes Manager) is provided direct by Insulet and should not be requested by the prescriber/billed to the plan.)</u></p> <p><u>This policy does not apply to pumps reviewed and/or covered by the Medical Benefit including, but not limited to V-Go 24-hour disposable system and continuous pumps such as MiniMed and t:slim X2. Requests for these products are referred to the plan's Utilization Management team for review.</u></p>
<u>Covered Uses</u>	<u>Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.</u>
<u>Exclusion Criteria</u>	<u>None</u>
<u>Required Medical Information</u>	<u>See "Other Criteria"</u>
<u>Age Restrictions</u>	<u>None</u>
<u>Prescriber Restrictions</u>	<u>Prescribed by or in consultation with an endocrinologist</u>
<u>Coverage Duration</u>	<p><u>If all of the criteria are met, the request will be approved for 12 months.</u></p> <p><u>If the criteria are not met, the request is referred to a Medical Director/Clinical Reviewer for medical necessity review.</u></p>
<u>Other Criteria</u>	<p><u>Initial Authorization</u></p> <ul style="list-style-type: none"> • <u>Diagnosis – diabetes</u> • <u>One of the following</u> <ul style="list-style-type: none"> ○ <u>≤ 18 years with type 1 diabetes or other insulin-deficient forms of diabetes (i.e. cystic-fibrosis related diabetes)</u> ○ <u>Continuation of therapy for patient new to plan</u> ○ <u>Treatment with multiple daily doses (≥ 3) of insulin and one of the following</u> <ul style="list-style-type: none"> ▪ <u>Persistently inadequate glycemic control (i.e. HbA1C ≥ 7% on multiple consecutive readings with one being within the last 3 months, frequent bouts of</u>

<p><u>Revision/Review</u> <u>Date 6/2021</u></p>	<p><u>hypoglycemia, overt microvascular complications)</u></p> <ul style="list-style-type: none">▪ <u>History of acutely dangerous symptoms (i.e. severe glycemic excursions; brittle diabetes; nocturnal hypoglycemia; hypoglycemia unawareness, ketosis)</u>▪ <u>Other difficult to manage symptoms/scenarios (i.e. “dawn” phenomenon; extreme insulin sensitivity; very low insulin requirements)</u>▪ <u>Pregnancy</u> <p><u>Reauthorization</u></p> <ul style="list-style-type: none">• <u>One of the following:</u><ul style="list-style-type: none">○ <u>Child or adolescent with type 1 diabetes or other insulin-deficient form of diabetes</u>○ <u>Documentation of positive clinical response (i.e. improved HbA1C; reduced frequency of severe hypoglycemia episodes; target time in range [TIR] > 70% or time below range < 4%) with 1st reauthorization</u>○ <u>Initial approval was based on continuation of therapy for patient new to plan.</u>• <u>Continuation of therapy based on a diagnosis of pregnancy alone is not eligible for reauthorization</u> <p><u>Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.</u></p>
--	--